Swedish Orphan Biovitrum's distribution agreements with Shire to be discontinued as Shire sets up own Nordic sales organization

  Stockholm, Sweden - September 16, 2010 - Swedish Orphan Biovitrum (STO: SOBI)
today announced that they will discontinue their marketing, distribution and
medical support of Xagrid, Fosrenol, and Equasym  in the Nordic countries when
the various distribution contracts with Shire expire during 2011. The reason for
the termination of the partnership is that Shire intends to establish a
marketing and sales organization in the Nordic region that will take care of
these products.

  The total yearly sales of the products in the Nordic countries is some 90
MSEK. Swedish Orphan Biovitrum resources that have supported the products will
be used to fill resource gaps for products in the launch phase such as Yondelis,
Multiferon and Ruconest.

  "We  are grateful for the very long  and successful partnership with Shire. We
also  wish them  the best  of luck  as they  set up  their own  organization and
continue  to provide these  valuable products to  patients who need  them in the
Nordic  countries. Since we  will be able  to transfer resources  devoted to the
Shire products to new products with strong growth opportunities, the revenue and
profit impact will be limited" said Kennet Rooth, Head of Marketing and Sales at
Swedish Orphan Biovitrum.

  "Sobi and Shire have worked well together over a period of more than 12 years.
This  collaboration between Sobi and  Shire has enabled us  to bring several new
medicines  to the Nordic region to benefit patients in specialist fields such as
haematology  and  nephrology  at  a  time  when  Shire  did  not  have  its  own
infrastructure in these countries.  I appreciate the professionalism of the Sobi
management  team and staff and thank them for the quality of their services over
the years," said Tim Tustin, VP and Managing Director, Export at Shire.

  About Swedish Orphan Biovitrum

  Swedish  Orphan Biovitrum  is a  Swedish based  niche specialty pharmaceutical
company  with  an  international  market  presence.  The  company  is focused on
providing  and developing  specialist pharmaceuticals  for rare disease patients
with  high medical needs.  The portfolio consists  of about 60 marketed products
and  an emerging late stage clinical development pipe-line. Our focus areas are:
hemophilia,   inflammation/autoimmune   diseases,   fat   malabsorption,  cancer
supportive  care and inherited metabolic disorders. Swedish Orphan Biovitrum had
pro-forma  revenues 2009e of  about 2 BSEK  and approximately 500 employees. The
head  office is located in Sweden and the  share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. For more information please visit www.sobi.com.


  For more information please contact: Swedish Orphan Biovitrum AB (publ):

  Kennet Rooth, VP Marketing and Sales
Phone. +46 8 697 23 30

  Erik Kinnman, VP Investor Relations
Phone: +46 73 422 15 40
E-mail:erik.kinnman@sobi.com


  Swedish  Orphan Biovitrum may be required to disclose the information provided
herein  pursuant  to  the  Swedish  Securities  Markets Act. The information was
provided for public release on September 16, 2010 at 4 p.m. CET.



[HUG#1444884]